Table 2 Comparison between the three drugs as regards changes in attack duration (hours), frequency (number/month), severity of headache (VAS), duration of vertiginous attack (hours), and its frequency (number/ month) before and after medical treatment (Kruskal–Wallis and one-way ANOVA tests)
Mean ± SD | Range (min.–max.) | P value | Sig | ||
|---|---|---|---|---|---|
Attack duration of headache | K | ||||
Cinnarzine group | − 0.30(± 0.53) | − 0.98–1.00 | 1.38 | 0.502 | NS |
Propranolol group | − 0.04(± 0.39) | − 0.96–0 | |||
Topiramate group | 0.91(± 4.11) | − 0.98–11.00 | |||
Frequency of headache | F | ||||
Cinnarzine group a,b | − 0.17 (± 0.30) | − 0.75–0 | 9.47 | 0.009 | HS* |
Propranolol group b,a | − 0.43 (± 0.36) | − 0.95–0 | |||
Topiramate group c,b | − 0.55 (± 0.16) | − 0.88–(− 0.25) | |||
Severity of headache | F | ||||
Cinnarzine group a,b | − 24 (± .21) | − .57–.13 | 3.59 | 0.036 | S* |
Propranolol group b,a | − 34 (± .17) | − .56–.00 | |||
Topiramate group c,b | − 40 (± .13) | − .60–(− .13) | |||
Duration of vertiginous attacks | K | ||||
Cinnarzine group | 2.80 (± 12.27) | − 1.00–47.0 | 3.78 | 0.151 | NS |
Propranolol group | − 0.57 (± 0.39) | − 0.97–0 | |||
Topiramate group | 0.76 (± 0.34) | − 1.00–0 | |||
Frequency of vertiginous attacks | F | ||||
Cinnarzine group | − 0.43 (± 0.39) | − 0.97–0.33 | 0.48 | 0.621 | NS |
Propranolol group | − 0.53 (± 0.31) | − 0.88–0 | |||
Topiramate group | − 0.55 (± 0.34) | − 0.94–0 |